@article{fdi:010064704,
  title = {{T}enofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in {A}frican {HIV}-infected patients : {ANRS} 12115 {DAYANA} substudy},
  author = {{L}e, {M}. {P}. and {L}andman, {R}. and {K}oulla-{S}hiro, {S}. and {C}harpentier, {C}. and {S}ow, {P}. {S}. and {D}iallo, {M}. {B}. and {G}ueye, {N}. {F}. {N}. and {N}golle, {M}. and {L}e {M}oing, {V}. and {E}ymard-{D}uvernay, {S}abrina and {B}enalycherif, {A}. and {D}elaporte, {E}ric and {G}irard, {P}. {M}. and {P}eytavin, {G}.},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjectives: {A}n open-label randomized trial ({DAYANA}) was conducted in sub-{S}aharan settings to evaluate four different regimens containing tenofovir disoproxil fumarate as first-line treatment for {HIV} infection. {T}he objectives of the present substudy were to assess the relationship between trough concentrations of tenofovir in plasma collected after 24 h ({C}-24) and estimated glomerular filtration rates (e{GFR}) calculated by the different formulae that are available. {M}ethods: {T}he criteria for eligibility were those of the {DAYANA} trial, recruiting naive patients. {T}he four tenofovir regimens were: {G}roup 1, tenofovir/emtricitabine/nevirapine; {G}roup 2, tenofovir/lopinavir/ritonavir; {G}roup 3, tenofovir/emtricitabine/zidovudine; and {G}roup 4, tenofovir/emtricitabine/efavirenz. {T}he {C}-24 of tenofovir was determined using {LC}-{MS}/{MS}. {T}he e{GFR} was calculated using the {C}ockcroft-{G}ault, {M}odification of {D}iet in {R}enal {D}isease ({MDRD}) and {C}hronic {K}idney {D}isease {E}pidemiology {C}ollaboration ({CKD}-{EPI}) formulae. {R}esults: {T}he median {C}-24 of tenofovir was 42 ng/m{L}. {T}he {C}-24 of tenofovir was higher with lopinavir/ritonavir than with the other three regimens: at {W}eek 4, 84 ng/m{L} versus 25 ng/m{L}; and at {W}eek 48, 81 ng/m{L} versus 52 ng/m{L}. {T}he baseline merged e{GFR} was 98.2 m{L}/min/1.73 m(2) with the {CKD}-{EPI} equation. {O}nly the mean changes in e{GFR} in {G}roup 2 differed from the absolute value of zero (-.2 m{L}/min/1.73 m(2)) with the {CKD}-{EPI} equation between baseline and {W}eek 48. {T}he {C}ockcroft-{G}ault formula is inappropriate for these {A}frican patients because it underestimated the baseline e{GFR} and overestimated the changes in e{GFR} between baseline and {W}eek 48. {C}onclusions: {I}n this population of mostly female {HIV}-1-infected {A}frican patients, tenofovir plasma overexposure was associated with {PI}/ritonavir and a time-dependent decrease in e{GFR}, probably via an inhibition of {MRP}2/{MRP}4 efflux transporters. {T}he close monitoring over time of the e{GFR} using {MDRD} or {CKD}-{EPI} calculations and by using other biomarkers of renal disorder should be proposed as an alternative to therapeutic drug monitoring in resource-limited countries.},
  keywords = {antiretroviral therapy ; {ART} ; drug monitoring ; {SENEGAL} ; {CAMEROUN} ; {AFRIQUE} {SUBSAHARIENNE}},
  booktitle = {},
  journal = {{J}ournal of {A}ntimicrobial {C}hemotherapy},
  volume = {70},
  numero = {5},
  pages = {1517--1521},
  ISSN = {0305-7453},
  year = {2015},
  DOI = {10.1093/jac/dku532},
  URL = {https://www.documentation.ird.fr/hor/fdi:010064704},
}